Burning Rock Schedules Third Quarter of 2021 Earnings Release on November 16, 2021
Burning Rock Biotech Limited (NASDAQ: BNR) announced its plans to release unaudited financial results for Q3 2021 on November 16, 2021, prior to U.S. market opening. The company will hold a conference call at 8:00 a.m. ET to discuss the results. Burning Rock specializes in next generation sequencing (NGS) technology for precision oncology, claiming a leading market share in China with over 273,000 tests completed. Investors can access the earnings release via their investor relations website.
- Leading market share in China for NGS-based therapy selection testing.
- Over 273,000 NGS tests completed cumulatively.
- None.
GUANGZHOU, China, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company foused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the third quarter of 2021 before the U.S. market opens on November 16, 2021. Following the release, company management will host a conference call at 8:00 a.m. ET (9:00 p.m. Hong Kong time) on the same day to discuss its financial results for the third quarter of 2021.
Details of the conference call are as follows:
| International: | +65 67135590 |
| U.S.: | +1 3322089468 |
| U.K.: | +44 2036928125 |
| Hong Kong: | +852 30186771 |
| China Mobile: | 4008205286 |
| China Landline: | 8008208659 |
| Conference ID: | 2277434 |
A replay of the conference call will be available for one week (dial-in number: 2277434; same conference ID as shown above).
Please visit the Company’s investor relations website at https://ir.brbiotech.com/news-events/news-releases on November 16, 2021 to view the earnings release prior to the conference call.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 273,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit: www.brbiotech.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
Contact: IR@brbiotech.com
FAQ
When will Burning Rock Biotech release its Q3 2021 financial results?
What is Burning Rock Biotech's stock symbol?
What time is the conference call for Burning Rock's Q3 results?
How many tests has Burning Rock completed?
